At a glance
- Originator Kyowa Hakko
- Class Antineoplastics
- Mechanism of Action DNA synthesis inhibitors; DNA-directed DNA polymerase inhibitors; Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer